2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2680

Determinants of Fatigue in Patients with Primary SjöGren’s Syndrome and Impact of Fatigue on Patients’ Treatments: A Cohort Study
Abstract Number: 3233

Determinants of Pain, Fatigue, Physical Function and Social Participation in SLE Patients, Measured with Patient Reported Outcomes Measurement Information System (PROMIS®) Computerized Adaptive Tests
Abstract Number: 3186

Determinants of Patient-Physician Discordance in Global Assessment in Psoriatic Arthritis and Levels of Discordance According to Disease Activity: A Multicenter European Study
Abstract Number: 1480

Determination of the Lipid Profile in Active Disease Leads to Incorrect Cardiovascular Risk Prediction in Early Rheumatoid Arthritis Patients
Abstract Number: 1903

Determining Disease Course in Localized Scleroderma: A Prospective Cohort Study
Abstract Number: 1051

Determining the Minimal Clinically Important Difference for Improvement for Systemic Lupus Erythematosus Disease Activity Index-2000 Responder Index-50 (S2K RI-50)
Abstract Number: 2022

Developing a Gout Needs Assessment Incorporating Patient Perspective on Self-Management, Self-Efficacy and Disease Specific Knowledge, to Inform a Patient Education Initiative
Abstract Number: 2397

Developing a Role for 18f-Flurodeoxyglucose PET/MRI in Pediatric Takayasu Arteritis
Abstract Number: 422

Developing a Staff-Driven Electronic Smoking Cessation Referral Program in Rheumatology Clinics
Abstract Number: 686

Development and Evaluation of the Combined Ankylosing Spondylitis Spine Score (CASSS) for the Assessment of Spinal Radiographic Outcome
Abstract Number: 3060

Development and Implementation of a Question-Based Tool Promoting Learning of Relevant Epidemiology and Biostatistics in Rheumatology: The Critical Literature Assessment Skills Support – Rheumatology (CLASS-Rheum) Pilot
Abstract Number: 794

Development and Initial Validation of a Novel Lupus Disease Activity Index to Account for Glucocorticoids: Sledai-2K Glucocorticoids Index (SGI)
Abstract Number: 3005

Development and Initial Validation of the “MH Score”, a New Diagnostic Tool That Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome
Abstract Number: 408

Development and Initial Validation of the Parent and Child Versions of the Juvenile Arthritis Disease Activity Score
Abstract Number: 3130

Development and Pilot Testing of an Online Educational Tool for Gout Patients — Mygoutcare®

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].